

# APRESENTAÇÃO - PÔSTERES - SLEP 2019

21.NOVEMBRO - QUINTA-FEIRA - 13:20-14:50

Área de Exposição - Espaço Tuguá

CÓD. PÔSTER	TÍTULO
PP1	Childhood adrenocortical carcinoma: Case report
PP2	Clinical and biochemical features at the diagnosis of a large cohort of patients diagnosed with the classic form of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
PP3	Congenital Adrenal Hyperplasia (CAH): Case report of a compound heterozygote CYP21A2 mutation with high glucocorticoids (GC) sensibility
PP4	CONGENITAL ADRENAL HYPERPLASIA: Clinical and molecular profile of newborns detected after 5 years of public screening program implementation
PP5	Differential Diagnosis of Virilization in Prepubertal Children: Case Report
PP6	Early diagnosis of adrenocortical carcinoma due to elevated 17-hydroxyprogesterone in newborn screening.
PP7	Experience in a Screening program for Congenital Adrenal Hyperplasia between 2010-2018
PP15	A girl with short stature
PP16	Adherence and long-term outcomes of therapy in pediatric subjects in Argentina using easypod™ electromechanical device for growth hormone treatment: the Phase IV multicentre Easypod™ Connect Observational Study (ECOS)
PP17	ANALYSIS OF SURVEY CARRIED OUT TO CHILEAN PROFESSIONALS ON THE PERCEPTION OF ADHERENCE OF PEDIATRIC PATIENTS TREATED WITH GROWTH HORMONE
PP18	Clinical characterization of patients with intrauterine growth restriction treated with growth hormone and cardiovascular risk factors
PP19	Excellent response to Growth Hormone and GnRH analogue treatment in a patient with Floating Harbor Syndrome
PP20	Growth and clinical characteristics of children with Floating-Harbor syndrome: analysis of current original data and a review of the literature
PP21	Growth hormone (GH) therapy in disproportionate short children with skeletal dysplasias
PP28	Acute Disseminated Encephalomyelitis (ADEM) preceding Type 1 Diabetes: What is the role of anti-GAD?
PP29	Association between hyperinsulinemia and Helicobacter pylori infection
PP30	Association between IGF-1 and non-alcoholic fatty liver disease in adolescents with type 2 diabetes mellitus
PP31	Changing the management of neonatal diabetes by means of genetic studies
PP32	Chronic mucocutaneous candidiasis and type 1 Diabetes in a child with STAT1 gain of function heterozygous mutation.
PP33	Clinical and laboratory characteristics in Mexican adolescents with newly diagnosed Type 2 Diabetes.
PP34	Clinical, laboratory and glycemic variability profile in a group of T1DM patients attended at a Public University Hospital in the southeast Brazil
PP35	Congenital Hyperinsulinism: casuistry report in 10 years of work.
PP36	ENDOTHELIAL DYSFUNCTION AND ATHEROGENIC RISK FACTORS IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS.
PP46	Autoimmune polyglandular syndrome type 1 with unilateral renal hypoplasia.
PP47	Berardinelli Seip Syndrome: Case report
PP48	CHARACTERIZATION OF PATIENTS WITH SYNDROME OF MC CUNE ALBRIGHT AND ITS MUTATION OF THE GNSI GENE
PP49	Familial hypercholesterolemia: a case report
PP50	Giant cell tumor in a patient with Noonan syndrome
PP64	ATYPICAL PRESENTATION OF VITAMIN D DEPENDENT RICKETS TYPE 1A (VDDR 1A)
PP65	Body mass index presents a strong correlation with Dual X-Ray Absorptiometry-measured adiposity in pediatric patients with Osteogenesis Imperfecta
PP66	Bone evaluation of children and adolescents with Turner Syndrome by quantitative ultrasound of proximal phalanges (QUS)
PP67	Brucks Syndrome, a rare form of Osteogenesis Imperfecta
PP68	Evaluation of the osteometabolic profile of subjects in the transition phase who were treated with human recombinant growth hormone in childhood.
PP69	Follow up of surgical parathyroidectomy in chronic renal failure patients
PP70	Four novel PHEX gene mutations in patients with X-Linked Hypophosphatemia
PP77	Atypical presentation of prolactinoma in childhood.
PP78	Endocrinological effects of cancer and its treatment in childhood
PP79	LONG-TERM EVALUATION OF OVARIAN FUNCTION AND FOLLICULAR RESERVE IN PATIENTS WITH MALIGNANT DISEASES TREATED WITH CHEMOTHERAPY IN PREPUBERTAL OR PUBERTAL AGE

<b>PP80</b>	Men 1 presentation with insulinoma before 10 years old: case report
<b>PP81</b>	Peripheral precocious puberty secondary to sexual cord ovarian tumor with annular tubules (TCSTAs) not associated with Peutz-Jeghers syndrome (SPJ)
<b>PP82</b>	Evaluation of Inflammatory Markers, Metabolic Syndrome, hepatic steatosis and measurement of carotid intima in obese juvenile patients
<b>PP83</b>	Evaluation of visceral fat by ultrasound in children and adolescents
<b>PP84</b>	Hypovitaminosis D in a group of children with obesity and risk of metabolic syndrome.
<b>PP85</b>	IMPACT OF PROBIOTIC THERAPY INTERVENTION ON THE ANTHROPOMETRY OF OBESE CHILDREN AND ADOLESCENTS
<b>PP86</b>	LEVELS OF VITAMIN D AND ITS ASSOCIATION WITH EARLY MARKERS OF CARDIOVASCULAR DISEASE IN CHILDREN AND ADOLESCENTS WITH OVERWEIGHT OR OBESITY
<b>PP87</b>	NUTRITIONAL STATE OF ADOLESCENTS IN THE STATE OF GOIÁS, BRAZIL, IN 2008 AND 2018.
<b>PP95</b>	5 ALPHA REDUCTASE DEFICIENCY A FAMILY REPORT
<b>PP96</b>	Anti-Müllerian hormone reference values in paediatric population by electroquimioluminescence
<b>PP98</b>	Development of a LC-MS/MS method to measure simultaneously 10 sexual steroids in Pediatric Endocrinology.
<b>PP99</b>	Diagnostic Challenges in Sex Development Disorders: a Case Report
<b>PP100</b>	Disorders of sexual differentiation experience in the last five years in Mexican children.
<b>PP101</b>	Evolution of BMI in girls under GnRHa treatment for Idiopathic Central Precocious Puberty.
<b>PP102</b>	Final height evaluation in girls with constitutional early puberty in clinical follow-up.
<b>PP116</b>	A novel mutation in the thyroid hormone receptor $\beta$ gene in a patient who developed thyroid nodules
<b>PP117</b>	Antithyroid drug treatment in children and teenagers with Graves' disease
<b>PP118</b>	Congenital Hypothyroidism screening program: experience with a TSH lower cutoff in Buenos Aires City.
<b>PP119</b>	Conversion of hypothyroidism by Hashimoto's Thyroiditis (HT) to hyperthyroidism due to Graves Disease (GD) in a previously healthy child
<b>PP120</b>	Differential diagnosis of hepatitis in the course of methimazole treatment.
<b>PP121</b>	Differentiated thyroid carcinoma in children and adolescents: Clinical presentation, ATA risk-classification and prognosis
<b>PP128</b>	Intrathyroidal ectopic thymus mimicking thyroid nodules in children
<b>PP129</b>	Late diagnosis congenital hypothyroidism and abnormal activity of alpha-L Iduronidase (IDUA)
<b>PP130</b>	Methimazole therapy outcomes in pediatric hyperthyroidism
<b>PP131</b>	MUTATION OF THE THYROID HORMONE RECEPTOR AS A CAUSE OF RESISTANCE TO THYROID HORMONE.CASE REPORT
<b>PP132</b>	Mutations in Thyroid Hormone Beta Receptor Gene Identified in Children with Clinical Resistance to Thyroid Hormones
<b>PP133</b>	NEONATAL SCREENING PROGRAM IN THE CITY OF SANTA CRUZ, BOLIVIA, 10 YEARS OF EXPERIENCE
<b>PP134</b>	Newborn of mothers with Graves' disease: a case series
<b>PP135</b>	NUTRITIONAL STATUS AND INTELLIGENCE QUOTIENT IN KINDERGARTEN AND PRIMARY SCHOOL CHILDREN WITH THYROIDITIS BEFORE AND AFTER TREATMENT WITH LEVOTHYROXINE BISCUCUY. SUCRE MUNICIPALITY. PORTUGUESA STATE. VENEZUELA. JULY-OCTOBER 2017.
<b>PP136</b>	PAPILLARY THYROID CARCINOMA IN CHILDREN
<b>PP137</b>	PATIENT'S PROFILE CHARACTERIZATION OF DOWN SYNDROME AND CONGENITAL HYPOTHYROIDISM IN A NEONATAL SCREENING PROGRAM IN SOUTHERN BRAZIL
<b>PP138</b>	Pituitary Hyperplasia Simulating Pituitary Macroadenoma In A Child With Primary Hypothyroidism: A Case Report

## APRESENTAÇÃO - PÔSTERES - FINALISTAS - SLEP 2019

**21.NOVEMBRO - QUINTA-FEIRA - 13:20-14:50**

**Área de Exposição - Espaço Tuguá**

<b>CÓD. PÔSTER</b>	<b>TÍTULO</b>
<b>PPF1</b>	Cardio-metabolic risk factors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
<b>PPF2</b>	EHLERS-DANLOS SYNDROME: MOLECULAR AND CLINICAL CHARACTERIZATION OF TNXA/TNXB CHIMERAS IN CONGENITAL ADRENAL HYPERPLASIA PATIENTS
<b>PPF3</b>	Synchronization ontogeny between adrenal steroidogenesis genes and circadian rhythm of corticosterone secretion in rats.
<b>PPF4</b>	Response to growth hormone in very young children
<b>PPF5</b>	IMPACTS ON THE USE OF ZOLEDRONIC ACID IN PATIENTS WITH DIAGNOSIS OF OSTEOGENESIS IMPERFECTA EXPERIENCE IN 18 YEARS.